Published by PM360 – August 9, 2017 The growing power of payers in healthcare decision-making has put an increased emphasis on health economics and outcomes research (HEOR), as the data collected through that research is key to demonstrating the value of your drug. As HEOR teams have grown in importance, their roles have expanded to[…]
On this webinar, Dr. Richard Gliklich, CEO of OM1, discussed the evolving role of big data and cognitive computing in generating real-world evidence for cardiovascular and metabolic diseases. This session explored how innovative methodologies and technologies can be applied to support safety, value, and commercial strategies. Topics covered included: New real-world evidence methodologies and approaches[…]
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Value-based care is gaining momentum and with that so too are outcomes-based contracts and risk sharing agreements. As payment models increasingly link outcomes to payment, there is a greater need for alignment of outcomes among different stakeholders. Join Dr. Richard Gliklich as he discusses the opportunities and challenges with: Defining measurable outcomes Developing and implementing[…]
